Report Detail

Request for Sample of this report

Other Nuclear Medicine/Radiopharmaceutical Global Market – Forecast To 2027

  • RnM4214918
    • |
  • 25 September, 2020
    • |
  • Global
    • |
  • 602 Pages
    • |
  • IQ4I Research & Consultancy
    • |
  • Other

Over the past 50 years, the nuclear medicine field has displayed a strong link between investments in chemistry and the development of radionuclide and radio-labeled compounds which have impacted the healthcare practice. Nuclear medicine comprises diagnostic and therapeutic techniques that use radioisotopes for applications like oncology, cardiovascular and neurological disorders to provide information at both molecular and cellular levels for probing, tracking tissue function, study disease progression and assessing treatment responses.
The nuclear medicine global market is poised to grow at a high single digit CAGR from 2020 to 2027 to reach $10,742.7 million by 2027. Increasing radioisotopes applications, rise in public awareness, use of SPECT/CT and PET/CT imaging scans, the abundance of radiopharmaceuticals, advancement in imaging technology (hybrid imaging) and alpha therapy based targeted cancer treatment is boosting nuclear medicine market growth. In addition, increasing need in emerging markets, production of radiopharmaceuticals from cyclotrons, efficient diagnosis and treatments, emerging radio isotopes and replacement of old/traditional equipment are the opportunities likely to propel the growth of the nuclear medicine market.
The nuclear medicinal market is classified based on modality into diagnosis and therapeutics. The diagnostics market commanded the largest market revenue in 2020 and is expected to grow at a mid single digit CAGR from 2020 to 2027 due to an increase in SPECT and PET procedures. The therapeutics segment is projected to grow at high teen CAGR from 2020 to 2027 due to technological advancements in the targeted treatment of cancers. Potential new radioisotopes in the pipeline and advancement in neurological treatments are the key factors driving the growth of the therapeutics market. Diagnosis by products is segmented into SPECT and PET. SPECT market commanded the largest revenue in 2020 and is expected to grow at low single digit CAGR from 2020 to 2027 due to an increase in TC-99m isotope applications and product approvals. Among SPECT is segmented based on isotopes into Technetium (Tc-99m), Thallium (Tl-201), Gallium (Ga-67), Iodine (I-123), Samarium (Sm-153), Xenon (Xe-133), Rhenium (Re-186) and others. Technetium (Tc-99m) accounted for the largest share in 2020 and is projected to grow at a mid single digit CAGR from 2020 to 2027 due to its extensive usage in various diagnostic applications and emerging sources to meet the demand. SPECT market by application is segmented into cardiology, pulmonary, oncology, nephrology, neurology, inflammation, thyroid gland, lymphology and others. Cardiology accounted for the largest share in 2020 and is expected to grow at mid single digit CAGR from 2020 to 2027 due to an increase in the number of cardiac imaging cases using Tc-99m. Oncology is expected to grow at mid single digit CAGR from 2020 to 2027 due to increasing expanding usage in early screening tests in vulnerable populations in various developed countries.
PET is the fastest-growing segment with mid single digit CAGR from 2020 to 2027 due to an increase in the adoption of cyclotron for the production of PET isotopes increasing its availability. The PET isotopes include Fluorodeoxyglucose (18F-FDG), Gallium (Ga-68), Rubidium (Rb-82) and others. Fluorodeoxyglucose (18F-FDG) accounted for the largest share in 2020 and the market is expected to grow at mid single digit CAGR from 2020 to 2027. Gallium (Ga-68) is expected to grow at high double digit CAGR from 2020 to 2027 due to an increase in usage as theranostic pair in assessing the suitability of patient for Lutathera and many emerging targeted radiotherapy agents. PET by applications is segmented into cardiology, oncology, neurology, inflammation and others. Oncology accounted for the largest share in 2020 and is projected to grow at high single digit CAGR from 2020 to 2027 due to an increase in the patient pool of lung, thyroid, brain breast cancer and dementia related conditions.
The therapeutic nuclear medicine market is segmented based on radiation type into alpha radiation, beta radiation and brachytherapy. Beta radiation accounted for the largest share of in 2020 and is projected to grow at high double digit CAGR of from 2020 to 2027. Beta radiation therapy by isotopes is further segmented into Y-90, I-131, Lu-177, Sm-153, Re-186, Sr-89, Er-169 and others. Lu-177 commanded the largest share in 2020 and is expected to grow at high double digit CAGR from 2020 to 2027 due to increased adoption of Lu-177 based radiopharmaceuticals for the treatment of neuroendocrine tumor and anticipated launch of new treatment products based on the isotope. Strontium (Sr-89) is expected to grow at a strong CAGR from 2020 to 2027. Brachytherapy isotopes are further segmented into I-125, Cs-131, Ir-192, Pd-103 and others. I-125 market accounted for the largest share in 2020 and is projected to grow at low single digit CAGR from 2020 to 2027 due to increasing usage in the treatment of lung cancer, prostate cancer, eye-related disease (retinoblastoma and eye plaque) and brain cancer. Therapeutic nuclear medicine by application is segmented into prostate cancer, thyroid cancer, liver cancer, gastro-entero-pancreatic-neuroendocrine tumors (GEP-NETs), metastatic bone cancer, breast cancer and others. The GEP-NETs market accounted for the largest share in 2020 and is expected to grow at high double digit CAGR from 2020 to 2027. Prostate Cancer is expected to grow at a strong CAGR from 2020 to 2027 due to advanced clinical trial stage (phase 3) and predicted launch of Lu-177 PSMA-617 product in 2021.
Nuclear medicine based on end-user is segmented into hospitals, ambulatory centers, diagnostic centers and others. Hospital accounted for the largest share in 2020 and is projected to grow at high double digit CAGR from 2020 to 2027 due to the ready availability of cyclotrons for the generation of isotope and use of advanced hybrid imaging.
The stable isotope global market is expected to grow at low single digit CAGR from 2020 to 2027 to reach $284.3 million by 2027. The Nuclear Medicine market includes stable isotopes are classified into isotopes and applications. Isotopes considered are carbon (C-13), deuterium (D2), oxygen (O-18), nitrogen (N-15), Sulphur (S-32) and others. Deuterium (D-2) accounted the largest share n 2020 and is the fastest-growing market with a projected CAGR of 3.3% from 2020 to 2027 due to the use of deuterium as a dietary supplement of deuterium-depleted water which helps to extend the survival rate of lung cancer patient via exerting anticancer effect and modification of deuterium leads to the development of novel, highly differentiated drugs which have therapeutic applications in diabetic nephropathy, hot flashes, spasticity, neuropathic pain and multiple melanomas. The stable isotope applications market is segmented into diagnostics-therapy, pharmaceutical companies and others. The diagnostics and therapy market commanded the largest market revenue in 2020 and is expected grow at low single digit CAGR from 2020 to 2027 due to use in diagnosis and treatment of pancreas, liver and intestine related disorders. The pharmaceuticals is the fastest-growing segment at low single digit CAGR from 2020 to 2027 due to novel developments in the utilization of stable isotopes that involve biopolymers, where isotope-labeled species are generated from cells grown on labeled growth media.
Geographical wise, North American region commanded the largest revenue in 2020 and is expected to grow at low single digit CAGR from 2020 to 2027. The growing use of SPECT and PET scans, technological advancements in equipment, increased utilization of fusion imaging, increasing awareness of radiopharmaceuticals among radiologists, alpha radio-immunotherapy-based targeted cancer treatment are driving the market.
Some of the key players of the nuclear medicine market are Curium Pharma (France), Bayer Group (Germany), GE Healthcare (U.S.), Cardinal Health (U.S.), Jubilant Life science (India), Lantheus Medical Imaging (U.S.), Novartis International AG (Advanced accelerator) (Switzerland), South African Nuclear Energy Corporation (NTP Radioisotopes SOC Ltd) (South Africa), and Fujifilm Holding Corporation (Japan).
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)


1 EXECUTIVE SUMMARY 32

    2 INTRODUCTION 39

    • 2.1 KEY TAKE AWAY 39
    • 2.2 REPORT SCOPE 40
    • 2.3 REPORT DESCRIPTION 40
    • 2.4 MARKETS COVERED 43
    • 2.5 STAKEHOLDERS 46
    • 2.6 RESEARCH METHODOLOGY 47
      • 2.6.1 MARKET SIZE ESTIMATION 48
      • 2.6.2 MARKET CRACKDOWN AND DATA TRIANGULATION 51
      • 2.6.3 SECONDARY SOURCES 52
      • 2.6.4 PRIMARY SOURCES 53
      • 2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 53
      • 2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 54
      • 2.6.7 ASSUMPTIONS 55

    3 MARKET ANALYSIS 57

    • 3.1 INTRODUCTION 57
    • 3.2 MARKET SEGMENTATION 57
    • 3.3 FACTORS INFLUENCING MARKET 63
      • 3.3.1 DRIVERS AND OPPORTUNITIES 63
        • 3.3.1.1 Increasing applications of radiopharmaceuticals 63
        • 3.3.1.2 Production of radiopharmaceuticals from cyclotrons 65
        • 3.3.1.3 Efficient diagnosis and treatments 66
        • 3.3.1.4 Increasing interest in theranostics 67
        • 3.3.1.5 Rise in public awareness 68
        • 3.3.1.6 Technological advancements 69
        • 3.3.1.7 Increasing demand in emerging markets 70
      • 3.3.2 RESTRAINTS AND THREATS 71
        • 3.3.2.1 The shorter half-life of radiopharmaceuticals 71
        • 3.3.2.2 High cost and supply shortage of isotopes 71
        • 3.3.2.3 Radio toxicity 72
        • 3.3.2.4 Shortage of qualified technicians 73
        • 3.3.2.5 Withdrawal of radiopharmacy products due to limited commercial adoption 74
        • 3.3.2.6 Regulatory issues 75
        • 3.3.2.7 Threat from traditional/alternative diagnostic procedures 75
        • 3.3.2.8 Huge capital investment 76
    • 3.4 PROBLEM AREAS 77
      • 3.4.1 CLOSURE OF REACTORS 77
    • 3.5 WINNING IMPERATIVES 78
      • 3.5.1 AVAILABILITY OF TECHNETIUM 78
    • 3.6 REGULATORY GUIDELINES 79
      • 3.6.1 UNITED STATES 79
      • 3.6.2 EUROPE 80
      • 3.6.3 JAPAN 81
      • 3.6.4 INDIA 81
      • 3.6.5 CHINA 82
      • 3.6.6 SOUTH KOREA 82
    • 3.7 REIMBURSEMENT SCENARIO AND CHALLENGES 83
    • 3.8 CLINICAL TRIALS 90
    • 3.9 EMERGING ISOTOPES 92
    • 3.10 TECHNOLOGICAL ADVANCEMENTS 94
      • 3.10.1 COMPTON CAMERA 94
      • 3.10.2 SUBTLE PET 94
      • 3.10.3 PRODUCTION OF ISOTOPES THROGUH CYCLOTRONS 95
      • 3.10.4 LINAC BASED TC-99M PRODUCTION 95
      • 3.10.5 AUGER ELECTRONS 95
    • 3.11 SUPPLY CHAIN ANALYSIS OF NUCLEAR MEDICINE 96
      • 3.11.1 REACTORS 97
      • 3.11.2 CYCLOTRON 98
      • 3.11.3 GENERATORS 99
      • 3.11.4 LINAC BASED TC-99M PRODUCTION METHOD 100
      • 3.11.5 PROCESSING FACILITY 101
      • 3.11.6 HOSPITALS AND CENTRAL RADIO PHARMACIES 102
      • 3.11.7 SUPPLY CHAIN ANALYSIS OF LUTITIUM-177 (Lu-177) 102
      • 3.11.8 SUPPLY CHAIN ANALYSIS OF GALLIUM-68 (Ga-68) 104
      • 3.11.9 SUPPLY CHAIN ANALYSIS OF ACTINIUM-225 (Ac-225)

    AND BISMUTH-213 (Bi-213) 106

    • 3.11.10 SUPPLY CHAIN ANALYSIS OF RUBIDIUM (Rb-82) AND

    STRONTIUM-82 (Sr-82) 109

    • 3.11.11 SUPPLY CHAIN ANALYSIS OF RADIUM-223 (Ra-223) 110
  • 3.12 LIST OF POTENTIAL NEW REACTORS 111
  • 3.13 LIST OF FDA APPROVED RADIOPHARMACEUTICALS 112
  • 3.14 PORTER'S FIVE FORCE ANALYSIS 117
    • 3.14.1 THREAT OF NEW ENTRANTS 118
    • 3.14.2 THREAT OF SUBSTITUTES 118
    • 3.14.3 COMPETITIVE RIVALRY 118
    • 3.14.4 BARGAINING POWER OF SUPPLIERS 119
    • 3.14.5 BARGAINING POWER OF BUYERS 120
  • 3.15 MARKET SHARE ANALYSIS BY MAJOR PLAYERS 121
    • 3.15.1 NUCLEAR MEDICINE MARKET 121
    • 3.15.2 SPECT MARKET 125
    • 3.15.3 PET MARKET 128
    • 3.15.4 NUCLEAR MEDICINE THERAPEUTIC MARKET 130
    • 3.15.5 Tc-99 MARKET 133
    • 3.15.6 F-18 MARKET 135
    • 3.15.7 Ga-68 MARKET 137
    • 3.15.8 Rb-82 MARKET 139
  • 3.16 NUCLEAR MEDICINE-FUNDING SCENARIO 140
  • 3.17 NUCLEAR MEDICINE – DEALS AND APPROVALS 144

    • 4 NUCLEAR MEDICINE GLOBAL MARKET, BY MODALITY 155

    • 4.1 INTRODUCTION 155
    • 4.2 DIAGNOSTICS 162
      • 4.2.1 NUCLEAR MEDICINE FOR DIAGNOSIS, BY ISOTOPES 166
        • 4.2.1.1 SPECT, by isotopes 166
        • 4.2.1.1.1 Technetium (Tc-99m) 169
        • 4.2.1.1.2 Thallium (Tl-201) 173
        • 4.2.1.1.3 Gallium (Ga-67) 174
        • 4.2.1.1.4 Iodine (I-123) 176
        • 4.2.1.1.5 Samarium (Sm-153) 178
        • 4.2.1.1.6 Xenon (Xe-133) 179
        • 4.2.1.1.7 Rhenium (Re-186) 181
        • 4.2.1.1.8 Others (In-111, Y-90, Cr-51) 182
        • 4.2.1.2 PET, by isotopes 184
        • 4.2.1.2.1 Fluorodeoxyglucose (18f-Fdg) 187
        • 4.2.1.2.2 Gallium (Ga-68) 189
        • 4.2.1.2.3 Rubidium (Rb-82) 192
        • 4.2.1.2.4 Others (C-11, N-13, Cu-64, Zr-89) 195
        • 4.2.2 NUCLEAR MEDICINE FOR DIAGNOSIS, BY APPLICATION 196
          • 4.2.2.1 SPECT by application 196
          • 4.2.2.1.1 Cardiology 200
          • 4.2.2.1.2 Pulmonary 201
          • 4.2.2.1.3 Oncology 203
          • 4.2.2.1.4 Nephrology 205
          • 4.2.2.1.5 Neurology 206
          • 4.2.2.1.6 Inflammation 208
          • 4.2.2.1.7 Thyroid Glands 209
          • 4.2.2.1.8 Lymphology 211
          • 4.2.2.1.9 Others 212
          • 4.2.2.2 PET by application 214
          • 4.2.2.2.1 Oncology 219
          • 4.2.2.2.2 Neurology 220
          • 4.2.2.2.3 Cardiology 222
          • 4.2.2.2.4 Inflammation 223
          • 4.2.2.2.5 Others 225
          • 4.3 THERAPEUTICS 226
            • 4.3.1 NUCLEAR MEDICINE FOR THERAPEUTICS, BY RADIATION TYPE 227
              • 4.3.1.1 Beta Radiation Therapy 230
              • 4.3.1.1.1 Yttrium (Y-90) 234
              • 4.3.1.1.2 Iodine (I-131) 237
              • 4.3.1.1.3 Lutetium (Lu-177) 238
              • 4.3.1.1.4 Samarium (Sm-153) 242
              • 4.3.1.1.5 Rhenium (Re-186) 244
              • 4.3.1.1.6 Strontium (Sr-89) 245
              • 4.3.1.1.7 Erbium (Er-169) 247
              • 4.3.1.1.8 Others 248
              • 4.3.1.2 Alpha Radiation Therapy, By Isotopes (Ra-223) 250
              • 4.3.1.3 Brachytherapy, By Isotopes 258
              • 4.3.1.3.1 Iodine (I-125) 262
              • 4.3.1.3.2 Cesium (Cs-131) 263
              • 4.3.1.3.3 Iridium (Ir-192) 265
              • 4.3.1.3.4 Palladium (Pd-103) 266
              • 4.3.1.3.5 Others 268
              • 4.3.1.4 Nuclear Medicine Therapeutics, By Application 269
              • 4.3.1.5 Prostate Cancer 273
              • 4.3.1.6 Thyroid Cancer 275
              • 4.3.1.7 Liver Cancer 276
              • 4.3.1.8 GEP-NET Therapeutics 277
              • 4.3.1.9 Metastatic Bone Cancer Therapeutics 279
              • 4.3.1.10 Breast Cancer Therapeutics 280
              • 4.3.1.11 Other Applications 282

            5 NUCLEAR MEDICINE GLOBAL MARKET, BY END-USERS 284

            • 5.1 INTRODUCTION 284
            • 5.2 HOSPITAL 287
            • 5.3 AMBULATORY CENTERS 289
            • 5.4 DIAGNOSTIC CENTERS 291
            • 5.5 OTHER END-USERS 292

            6 STABLE ISOTOPES 294

            • 6.1 INTRODUCTION 294
            • 6.2 MARKET ANALYSIS 296
              • 6.2.1 FACTORS INFLUENCING MARKET 296
              • 6.2.2 DRIVERS AND OPPORTUNITIES 296
                • 6.2.2.1 Increase in research activities (pharmaceuticals and biotechnology sectors) 296
                • 6.2.2.2 Increasing applications 297
              • 6.2.3 RESTRAINTS AND THREATS 298
                • 6.2.3.1 High cost of stable isotopes 298
                • 6.2.3.2 Stable isotopes-side effects and safety issues 298
                • 6.2.3.3 Stringent regulations for manufacturing and use of stable isotopes 299
            • 6.3 STABLE ISOTOPES MARKET, BY ISOTOPE 299
              • 6.3.1 CARBON (C-13) 301
              • 6.3.2 DEUTERIUM (D2) 303
              • 6.3.3 OXYGEN (O-18) 305
              • 6.3.4 NITROGEN (N-15) 307
              • 6.3.5 SULPHUR (S-32) 308
              • 6.3.6 OTHERS 309
            • 6.4 STABLE ISOTOPES MARKET, BY APPLICATION 311
              • 6.4.1 INTRODUCTION 311
              • 6.4.2 DIAGNOSTICS AND THERAPY 314
              • 6.4.3 PHARMACEUTICALS 316
              • 6.4.4 OTHERS 318
            • 6.5 STABLE ISOTOPES MARKET, BY GEOGRAPHY 319
              • 6.5.1 INTRODUCTION 319
              • 6.5.2 NORTH AMERICA 321
              • 6.5.3 EUROPE 326
              • 6.5.4 ASIA-PACIFIC 329
              • 6.5.5 REST OF THE WORLD 333

            7 NUCLEAR MEDICINE GLOBAL MARKET BY REGION 338

            • 7.1 INTRODUCTION 338
            • 7.2 NORTH AMERICA 341
              • 7.2.1 U.S. 366
              • 7.2.2 REST OF N.A. 374
            • 7.3 EUROPE 381
              • 7.3.1 GERMANY 405
              • 7.3.2 FRANCE 412
              • 7.3.3 ITALY 419
              • 7.3.4 REST OF E.U. 426
            • 7.4 APAC 434
              • 7.4.1 JAPAN 458
              • 7.4.2 CHINA 465
              • 7.4.3 SOUTH KOREA 472
              • 7.4.4 REST OF APAC 479
            • 7.5 REST OF THE WORLD 486
              • 7.5.1 TURKEY 510
              • 7.5.2 BRAZIL 517
              • 7.5.3 OTHERS 524

            8 COMPETITIVE LANDSCAPE 532

            • 8.1 INTRODUCTION 532
            • 8.2 APPROVALS 532
            • 8.3 COLLABORATION 535
            • 8.4 ACQUISITION 535
            • 8.5 EXPANSION 537
            • 8.6 OTHERS 538

            9 MAJOR PLAYER PROFILES 541

            • 9.1 BAYER GROUP 541
              • 9.1.1 OVERVIEW 541
              • 9.1.2 FINANCIALS 542
              • 9.1.3 PRODUCT PORTFOLIO 545
              • 9.1.4 KEY DEVELOPMENTS 545
              • 9.1.5 BUSINESS STRATEGY 545
              • 9.1.6 SWOT ANALYSIS 546
            • 9.2 BRACCO S.P.A 547
              • 9.2.1 OVERVIEW 547
              • 9.2.2 FINANCIALS 547
              • 9.2.3 PRODUCT PORTFOLIO 547
              • 9.2.4 KEY DEVELOPMENTS 548
              • 9.2.5 BUSINESS STRATEGY 548
              • 9.2.6 SWOT ANALYSIS 549
            • 9.3 CARDINAL HEALTH INC. 550
              • 9.3.1 OVERVIEW 550
              • 9.3.2 FINANCIALS 551
              • 9.3.3 PRODUCT PORTFOLIO 552
              • 9.3.4 KEY DEVELOPMENTS 553
              • 9.3.5 BUSINESS STRATEGY 553
              • 9.3.6 SWOT ANALYSIS 554
            • 9.4 CDH INVESTMENTS (CDH GENTECH LTD), (SIRTEX LTD.) 555
              • 9.4.1 OVERVIEW 555
              • 9.4.2 FINANCIALS 555
              • 9.4.3 PRODUCT PORTFOLIO 555
              • 9.4.4 KEY DEVELOPMENTS 556
              • 9.4.5 BUSINESS STRATEGY 556
              • 9.4.6 SWOT ANALYSIS 557
            • 9.5 CURIUM PHARMA 558
              • 9.5.1 OVERVIEW 558
              • 9.5.2 FINANCIALS 558
              • 9.5.3 PRODUCT PORTFOLIO 558
              • 9.5.4 KEY DEVELOPMENTS 560
              • 9.5.5 BUSINESS STRATEGY 563
              • 9.5.6 SWOT ANALYSIS 564
            • 9.6 FUJIFILM HOLDINGS CORPORATION 565
              • 9.6.1 OVERVIEW 565
              • 9.6.2 FINANCIALS 566
              • 9.6.3 PRODUCT PORTFOLIO 569
              • 9.6.4 KEY DEVELOPMENTS 570
              • 9.6.5 BUSINESS STRATEGY 571
              • 9.6.6 SWOT ANALYSIS 572
            • 9.7 GE HEALTHCARE 573
              • 9.7.1 OVERVIEW 573
              • 9.7.2 FINANCIALS 574
              • 9.7.3 PRODUCT PORTFOLIO 576
              • 9.7.4 KEY DEVELOPMENTS 576
              • 9.7.5 BUSINESS STRATEGY 577
              • 9.7.6 SWOT ANALYSIS 578
            • 9.8 JUBILANT LIFE SCIENCES 579
              • 9.8.1 OVERVIEW 579
              • 9.8.2 FINANCIALS 580
              • 9.8.3 PRODUCT PORTFOLIO 585
              • 9.8.4 KEY DEVELOPMENTS 586
              • 9.8.5 BUSINESS STRATEGY 586
              • 9.8.6 SWOT ANALYSIS 587
            • 9.9 LANTHEUS MEDICAL IMAGING, INC. 588
              • 9.9.1 OVERVIEW 588
              • 9.9.2 FINANCIALS 589
              • 9.9.3 PRODUCT PORTFOLIO 592
              • 9.9.4 KEY DEVELOPMENTS 592
              • 9.9.5 BUSINESS STRATEGY 592
              • 9.9.6 SWOT ANALYSIS 593
            • 9.10 NOVARTIS INTERNATIONAL AG 594
              • 9.10.1 OVERVIEW 594
              • 9.10.2 FINANCIALS 595
              • 9.10.3 PRODUCT PORTFOLIO 598
              • 9.10.4 KEY DEVELOPMENTS 599
              • 9.10.5 BUSINESS STRATEGY 600

    Summary:
    Get latest Market Research Reports on Nuclear Medicine/Radiopharmaceuticals. Industry analysis & Market Report on Nuclear Medicine/Radiopharmaceuticals is a syndicated market report, published as Nuclear Medicine/Radiopharmaceutical Global Market – Forecast To 2027. It is complete Research Study and Industry Analysis of Nuclear Medicine/Radiopharmaceuticals market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$4,950.00
    		$6,750.00
    		$9,000.00
    		3,890.70
    		5,305.50
    		7,074.00
    		4,677.75
    		6,378.75
    		8,505.00
    		768,240.00
    		1,047,600.00
    		1,396,800.00
    		417,978.00
    		569,970.00
    		759,960.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo